AI-generated analysis. Always verify with the original filing.
Senti Biosciences, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, including a net loss of $14.5 million for Q4 2025 and $61.4 million for the full year. The company also provided updates on its clinical pipeline, including positive preliminary data for its lead program SENTI-202 in AML and the receipt of RMAT designation from the FDA.
Event Type
Disclosure
Mandatory
Variant
8-K
of Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 27, 2026 104 Cover Page Interactive Data File (embedded
| Metric | Value | Basis |
|---|---|---|
| Revenue | $0.02 | |
| Research and Development Expenses | $7.80 | |
| General and Administrative Expenses | $5.80 | |
| Net Loss | $14.50 | |
| Basic and Diluted Net Loss Per Share | $0.53 |